» Articles » PMID: 23656388

First Trimester Maternal Serum Pregnancy-associated Plasma Protein-A is a Predictive Factor for Early Preterm Delivery in Normotensive Pregnancies

Overview
Publisher Informa Healthcare
Date 2013 May 10
PMID 23656388
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

In this study, we investigated whether the concentrations of pregnancy-associated plasma protein-A (PAPP-A) or free β-hCG (fβhCG) in the first trimester can identify women at increased risk of subsequent preterm delivery in the absence of hypertensive disorders. Preterm and early preterm deliveries are defined as those deliveries before completing 37 and 34 weeks, respectively. A total of 868 women were enrolled into this study. According to the level of the markers, the patients were evaluated in three groups: 1 - maternal serum level ≤ 5 th percentile, 2 - between 5th and 95th percentiles, 3 - ≥ 95 th percentile. In the group of patients with a PAPP-A level ≤ 5 th percentile [≤ 0.35 multiples of the median (MoM)], mean gestational age (GA) at delivery, mean birth weight and the number of the cases with early preterm delivery were significantly lower than the others. Mean level of PAPP-A was significantly lower in cases with early preterm than term deliveries (0.58 ± 0.32 versus 1.09 ± 0.69; p = 0.01). Maternal serum level of fβhCG did not show significant difference between these groups (0.84 ± 0.45 versus 1.17 ± 0.77; p = 0.15). Low levels of maternal serum PAPP-A (≤ 0.35 MoM) (Odds ratio = 7; 95% confidence interval 1.8-27.7; p = 0.0048) significantly predicted early preterm delivery in normotensive pregnancies. Women with low levels of PAPP-A at first trimester have a higher risk of early preterm delivery even in the absence of hypertensive disorders.

Citing Articles

Evaluating the predictive efficacy of first trimester biochemical markers (PAPP-A, fβ-hCG) in forecasting preterm delivery incidences.

Swiercz G, Zmelonek-Znamirowska A, Szwabowicz K, Armanska J, Detka K, Mlodawska M Sci Rep. 2024; 14(1):16206.

PMID: 39003389 PMC: 11246412. DOI: 10.1038/s41598-024-67300-6.


Prediction of Pregnancy Complications With Maternal Biochemical Markers Used in Down Syndrome Screening.

Ozdemir S, Sahin O, Acar Z, Demir G, Ermin E, Aydin A Cureus. 2022; 14(3):e23115.

PMID: 35425672 PMC: 9003626. DOI: 10.7759/cureus.23115.


The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study.

Pakniat H, Bahman A, Ansari I J Obstet Gynaecol India. 2019; 69(5):412-419.

PMID: 31598043 PMC: 6765032. DOI: 10.1007/s13224-019-01217-3.


Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia.

Nissaisorakarn P, Sharif S, Jim B Curr Cardiol Rep. 2016; 18(12):131.

PMID: 27837384 DOI: 10.1007/s11886-016-0782-1.


Maternal Serum Aneuploidy Screen and Adverse Pregnancy Outcomes.

Godbole K, Kulkarni A, Kanade A, Kulkarni S, Godbole G, Wakankar A J Obstet Gynaecol India. 2016; 66(Suppl 1):141-8.

PMID: 27651593 PMC: 5016434. DOI: 10.1007/s13224-015-0826-2.